CMP vs Fascia Iliaca Block

L

Loyola University

Status

Enrolling

Conditions

Pain, Postoperative
Hip Arthroplasty

Treatments

Drug: CMP
Drug: Fascia Illica

Study type

Interventional

Funder types

Other

Identifiers

NCT04426058
213048

Details and patient eligibility

About

Complete motorsparing protocol (CMP) has been developed to try to minimize the motor nerve block that is created when using Facia iliaca nerve block. The blocks performed in the (CMP) are the cluneal nerve block, Pericapsular nerve group block and lateral femoral cutaneous block. On the clinical trial, the investigators will randomize the participants that meet criteria to CMP or Fascia iliaca Block and compare the amount of opioid needed post op during 24 hours and their pain scores.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Patients ≥ 18 years old
  • Patients undergoing total hip arthroplasty posterior approach.
  • Patients willing to participate and sign informed consent

Exclusion criteria

  • Severe COPD/other contraindication to general anesthesia that spinal would be more suitable.
  • Patient with a weight of less than 41 kg
  • Dementia, not alert or Oriented to person, place, or time
  • Chronic pain patient with daily opioid use at home.
  • Patient with allergy to local anesthetics
  • Patient refusal
  • Total hip arthroplasty revision
  • Concomitant pain in different area from operative site.
  • Pregnancy
  • Patient with active infection on the injection sites for the blocks
  • Patients unable or willing to understand or comply with the study protocol

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

40 participants in 2 patient groups

CMP
Experimental group
Description:
Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
Treatment:
Drug: CMP
Fascia iliaca
Active Comparator group
Description:
Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
Treatment:
Drug: Fascia Illica

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Michael Majewski, MD; Carlos Martinez Parra, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems